# Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations

> **NCT06279130** · PHASE2,PHASE3 · RECRUITING · sponsor: **The Netherlands Cancer Institute** · enrollment: 133 (estimated)

## Conditions studied

- Resectable MMR-deficient Solid Tumors
- Resectable MMR-proficient Solid Tumors

## Interventions

- **DRUG:** botensilimab
- **DRUG:** balstilimab
- **DRUG:** FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)

## Key facts

- **NCT ID:** NCT06279130
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-29
- **Primary completion:** 2029-01-29
- **Final completion:** 2034-01-29
- **Target enrollment:** 133 (ESTIMATED)
- **Last updated:** 2026-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06279130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06279130, "Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06279130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*